- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05535426
[Trial of device that is not approved or cleared by the U.S. FDA]
April 28, 2026 updated by: [Redacted]
The aim of this Pilot Study is to demonstrate the safety and efficacy of the use of Tetranite Implant Stabilization Material (TN-ISM) in delivering enhanced stability to immediately restored dental implants inserted into fresh extraction sockets, with both clinical and patient-related successful outcomes.
Study Overview
Status
Withheld
Conditions
Intervention / Treatment
Detailed Description
The purpose of the present study is to evaluate the safety and efficacy of a single stage approach using Tetranite Implant Stabilization Material (TN-ISM).
The purpose of the efficacy component of this study is a composite comprising: (1) First - To demonstrate and evaluate the ability of TN-ISM to achieve immediate implant stabilization in sites otherwise unable to provide primary stability without requiring the delay in treatment imposed by the current multi-staged standard-of-care method; (2) Second - To demonstrate and evaluate the ability of TN-ISM to achieve increasing short-term stabilization of implants as the device undergoes initial resorption and replacement with new bone; (3) Third - To demonstrate the ability of TN-ISM to aid in the maintenance of alveolar ridge contours without buccal plate collapse and loss of crestal bone height; and Fourth (4) - To demonstrate and evaluate the ability of a TN-ISM stabilized implant to achieve implant success (after criteria of Buser, et.
al 1) after 12 months in situ while the device undergoes significant resorption, facilitates osteoconduction, and replacement with new bone.
In addition to the Primary Endpoints of establishing the Safety and Efficacy of Implant Stabilization and Implant Success throughout the initial 12 months of post-implant and device placement, the study also assesses several secondary endpoints over the course of the study and one-year follow-up, as outlined in the sections below.
These include assessment of incidence, duration, and severity of adverse effects and events; assessment of increasing implant stiffness; assessment of bone levels, bone volumetric changes; patient satisfaction surveys, and assessment of periodontal and peri-implant health integral to implant success.
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, W1G 7JD
- Recruiting
- Norton Implants
-
Contact:
- Michael R Norton
- Phone Number: 020 7486 9229
- Email: drnorton@nortonimplants.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects must have voluntarily signed the informed consent form before any study related procedures;
- Subjects must be males or females who are a minimum of 20 years of age;
- Subjects who require a single anterior maxillary tooth extraction and desire a replacement with a dental implant and immediate temporary crown. Candidate subjects may require more than one extraction, and all sitesbut only one site will be considered for inclusion in the study;
- Subjects must have opposing dentition (natural teeth, fixed or removable restorations);
- Subjects must be committed to the study and the required follow-up visits;
- Subjects must be American Society of Anesthesiology Grade (ASA) I or ASA II;
- Subjects who present with a sound bony housing with a visible buccal plate evident at the crest and fenestrations limited to <5.0mm diameter on a cone beam CT;
- Subjects who present with a sound bony housing with a visible buccal plate evident at the crest and dehiscences limited to <3.0mm in any direction on a cone beam CT;
- There must be sufficient bone height crestal to critical anatomical structures, i.e., the piriform foramen, and maxillary sinus, to safely place a dental implant within the bone contours. Extraction sockets should be able to accommodate an implant ≥9.0mm in length;
- Anatomical conditions must be present to allow an implant crown restoration to be placed at the candidate site, e.g., sufficient interocclusal space, incisal Class1 or Class 2 Div 1 relation, appropriate angulation of the ridge, etc.
Exclusion Criteria:
- There is at least 2mm of apical bone below the apex of the extraction socket for positive seating of the implant;
- Any implant site in which placement of the selected implant leaves an (Horizontal Dimension of Defect) HDD > 2mm in the buccal direction between the implant surface and the labial plate at the most coronal aspect of the extraction socket.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Tetranite Stabilized Dental Implants with Provisional Crown
Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites.
A provisional crown will also be inserted during this surgery.
|
Dental adhesive for increased implant stabilization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Stabilization by Resonance Frequency Analysis
Time Frame: 12 months
|
The primary endpoint is sufficient bone-to-implant interfacial stiffness post-placement of the implant stabilized by TN-ISM, whereby, sufficient bone-to-implant interfacial stiffness is measured by Resonance Frequency Analysis (RFA) expressed as mean Implant Stability Quotient (ISQ) at 12 months post TN-ISM device and implant placement.
For the study to be considered successful, the lower bound of the one-sided 97.5% confidence interval for the mean ISQ should exceed the clinical threshold of 60.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Stabilization by Resonance Frequency Analysis
Time Frame: 15 minutes, 3 months, and 7 months
|
Sufficient bone-to-implant interfacial stiffness measured by Resonance Frequency Analysis (RFA) expressed as Implant Stability Quotient (ISQ) at 15 minutes, 3 months, and 7 months post TN-ISM device and implant placement.
For each timepoint to be considered successful, the lower bound of the one-sided 97.5% confidence interval for the mean ISQ should exceed the clinical threshold of 60;
|
15 minutes, 3 months, and 7 months
|
|
Device Related Adverse Events
Time Frame: 12 months
|
Low incidence, severity and duration of device-related adverse events throughout the 12 months post TN-ISM device and implant placement follow-up period
|
12 months
|
|
Implant Stabilization by Manual Palpation
Time Frame: 15 minutes, 1 month, 3 months, and 7 months
|
Immediate implant stabilization demonstrated by lack of clinical mobility of the implant subjected to manual palpation in any direction at 15 minutes after application of the TN-ISM and at 1 month, 3 months and 7 months post TN-ISM device and implant placement;
|
15 minutes, 1 month, 3 months, and 7 months
|
|
Implant Success (Composite Measure)
Time Frame: 12 months
|
Composite measure of implant success (after criteria of Buser1) at 12 months post TN-ISM device and implant placement consisting of:
|
12 months
|
|
Volume Loss
Time Frame: 12 months
|
Crestal bone level maintenance assessed by analysis of two-dimensional periapical radiographic records showing no more than a 1.0mm loss of height throughout the 12 months post TN-ISM device and implant placement follow-up period
|
12 months
|
|
Per-implant tissue health
Time Frame: 12 months
|
Peri-implant tissue health demonstrated by direct measurement around the implant at 12 months post TN-ISM device and implant placement follow-up period as compared to existing conditions in the oral cavity near adjacent teeth to the implant site and to baseline around the implant at 3 months post placement
|
12 months
|
|
Patient Satisfaction
Time Frame: 12 months
|
Subject satisfaction using the patient-reported outcome measures
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 22, 2022
Primary Completion
March 1, 2024
Study Completion
March 1, 2024
Study Registration Dates
First Submitted
September 7, 2022
First Submitted That Met QC Criteria
September 9, 2022
First Posted (Actual)
September 10, 2022
Study Record Updates
Last Update Posted (Actual)
May 4, 2026
Last Update Submitted That Met QC Criteria
April 28, 2026
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DVAL 22004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.